UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of September 2018
COMMISSION
FILE Number.
000-29338
CORREVIO
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CORREVIO
PHARMA CORP. |
|
(Registrant) |
|
|
|
Date: September 5, 2018 |
By: |
/s/
Justin Renz |
|
|
Name: Justin Renz |
|
|
Title: Chief Financial Officer |
Exhibit 99.1
Correvio Reports Preliminary Data Collected
from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study
NASDAQ: CORV
TSX: CORV
Zero Deaths Reported,
Safety Outcomes of Interest Observed in 0.8% Cases
>70% of AF Episodes
Successfully Converted to Sinus Rhythm in a Median Time of 11 Minutes
VANCOUVER, Sept. 5, 2018 /CNW/ - Correvio Pharma
Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality
brands that meet the needs of acute care physicians and patients, today reported preliminary data from SPECTRUM, a post-authorization
safety study evaluating Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset
atrial fibrillation (AF), conducted in the European Union (EU).
SPECTRUM was conducted as part of the follow-up
measures agreed to with the European Medicines Agency in 2010. In this prospective and retrospective, observational registry, 1,778
unique patients with 2,009 treatment episodes were enrolled to describe patients receiving Brinavess and characterize and quantify
normal conditions of use, dosing and safety following administration of Brinavess. The data for SPECTRUM was provided by 53
participating hospitals in the EU and demonstrated that treatment with Brinavess successfully converted 70.2% (95% confidence
interval [CI] 68.1 – 72.2) of all treated patients. Treatment with Brinavess also showed a median time to conversion
of 11 minutes from start of first infusion among patients who converted.
In the safety results, a total of 19 health
outcomes of interest ("HOIs", defined as significant hypotension, ventricular arrhythmia, atrial flutter, or bradycardia)
were reported in 17 patients. The cumulative incidence of HOIs at study completion was 0.8% (95% CI: 0.5%-1.4%). Twenty-eight (28)
serious adverse events (SAEs) were reported for 26 patients and no deaths were reported in the study.
"This large European registry provides
important data on the safety, efficacy and use of Brinavess in 1,778 patients in a real-world setting," said Kiran Bhirangi,
M.D., Correvio's Vice President, Clinical Development and Medical Affairs. "In SPECTRUM, normal heart rhythm was restored
in over 70% of patients at a median time of 11 minutes, HOIs were observed in 0.8% of patients, and there were no deaths. SPECTRUM
efficacy and safety results compare well with what has been observed from a literature review of 18 Brinavess studies from
20 centers in 9 different countries. Collectively, these studies reported on an additional 1,361 patients treated with Brinavess
and demonstrated a median rate of cardioversion of approximately 74% (range 52.2% – 95%), a median time to cardioversion
of 11.8 minutes (range 8-62 minutes), and there were no deaths reported. We are encouraged by the consistency of the efficacy
and safety data observed in the clinical setting and we thank the SPECTRUM study investigators and the hospital site staff for
their hard work and commitment to this valuable registry."
About Atrial Fibrillation
Atrial Fibrillation (also known as AFib or
AF) is a supraventricular tachyarrhythmia with uncoordinated atrial activation resulting in ineffective atrial contraction and
if left untreated, structural and/or electrophysiological atrial tissue abnormalities.1 AF is a common cardiac rhythm
disturbance that increases in prevalence with advancing age.1 According to the American Heart Association, estimates
of the prevalence of AF in the U.S. ranged from 2.7 million to 6.1 million in 2010, and is expected to rise to between 5.6 million
to 12 million in 2030.2
There are two strategies to manage AF, namely,
rhythm- or rate-control. A rhythm-control strategy may be used in patients who are severely compromised, remain symptomatic despite
adequate rate control, when adequate rate control is difficult to achieve, when long term rhythm control therapy is preferred,
younger patient age, presence of tachycardia-mediated cardiomyopathy, and first episode of AF.1,3 Early intervention
with a rhythm-control strategy to prevent progression of AF may be particularly beneficial to the AF patient.1
About Brinavess®
Brinavess® (vernakalant
HCl, IV) is an antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse
conduction in a rate-dependent fashion. Brinavess is approved for marketing in Europe, Canada and
several other countries worldwide. In Europe, it is approved for the rapid conversion of recent onset atrial fibrillation
to sinus rhythm in adults: 1) for non-surgery patients: atrial fibrillation < 7 days duration; and 2) for post-cardiac
surgery patients: atrial fibrillation <3 days duration. Vernakalant IV is not approved for use in the United
States.
About Correvio Pharma Corp.
Correvio Pharma Corp. is a revenue-generating,
specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires
and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands
includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment
of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of
recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic
cardiovascular events in patients with acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol
hydrochloride), a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Correvio's
pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver treprostinil,
the world's leading treatment for pulmonary arterial hypertension. Correvio is traded on the NASDAQ Capital Market (CORV) and the
Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.
References
- January CT et al. 2014 AHA/ACC /HRS guideline for the
management of patients with atrial fibrillation. J AM Coll Cardiol. 2014;34:e1-e76.
- Mozaffarian D et al. Heart Disease and Stroke Statistics-2016
Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-60.
- Camm AJ et al. Guidelines for the management of atrial
fibrillation, The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J.
2010;31:2369-2429.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
"forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking
information" under applicable Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking
statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance,
capital expenditures, financing needs and other information that may not be based on historical fact. Forward-looking statements
can often be identified by the use of terminology such as "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect" and similar expressions.
Forward-looking statements are necessarily based on estimates and assumptions made by us based on our experience and perception
of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate.
These forward-looking statements may include,
but are not limited to: possible future meetings with the FDA, including the timing of any such meetings, and any possible regulatory
path forward with respect to BRINAVESS®; any potential cost savings or efficiency improvements for hospitals attributable
to the emergency room treatment of acute AF with Brinavess; our plans to develop and commercialize product candidates in various
countries and the timing of development and commercialization; whether we or our partners will receive, and the timing and costs
of obtaining, regulatory approvals for our products in various countries; clinical development of our product candidates, including
the results of current and future clinical trials and the timing associated with the receipt of clinical trial results; the ability
to enroll and to maintain enrollment of patients in our clinical trials; our estimates of the size of the markets and potential
markets for our products; our estimates of revenues and anticipated revenues for the commercialization of products and product
candidates; the range and degree of market acceptance of our products; the pricing of our products; and whether we will receive,
and the timing of, reimbursement for our products in various countries.
By their very nature, forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be
materially different from any future results, events or developments expressed or implied by such forward-looking statements. A
detailed discussion of the risks and uncertainties facing Correvio are discussed in the recent annual and quarterly reports of
our former parent company Cardiome Pharma Corp., the Short Form Base Shelf Prospectus filed on July 5, 2018 by Correvio, the Prospectus
Supplement filed July 10, 2018 by Correvio and those risks and uncertainties detailed from time to time in our other filings with
the Securities and Exchange Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities
at www.sedar.com. All of the risks and certainties disclosed in those filings are hereby incorporated by reference in their entirety
into this news release.
While Correvio makes these forward-looking
statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking
statements made in this presentation. All forward-looking statements made herein are based on our current expectations and we undertake
no obligation to revise or update such forward-looking statements to reflect subsequent events or circumstances, except as required
by law. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors
are cautioned not to put undue reliance on forward-looking statements due to their inherent uncertainty.
Correvio® and the Correvio Logo
are the proprietary trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used
under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used
under license.
Trevyent® is a trademark of SteadyMed Ltd. and used under license.
All other trademarks are the property of their respective owners.
View
original content:http://www.prnewswire.com/news-releases/correvio-reports-preliminary-data-collected-from-2-000-brinavess-treatment-episodes-in-eu-post-authorization-safety-study-300706777.html
SOURCE Correvio Pharma Corp
View original content: http://www.newswire.ca/en/releases/archive/September2018/05/c5347.html
%CIK: 0001036141
For further information: Justin Renz, CFO, Correvio Pharma
Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll/Claudia Styslinger, 212.600.1902,
michelle@argotpartners.com, claudia@argotpartners.com
CO: Correvio Pharma Corp
CNW 07:00e 05-SEP-18
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024